BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abboud H, Zheng C, Kar I, Chen CK, Sau C, Serra A. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. Mult Scler Relat Disord 2020;44:102249. [PMID: 32526698 DOI: 10.1016/j.msard.2020.102249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Ceglie G, Papetti L, Valeriani M, Merli P. Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. Int J Mol Sci 2020;21:E5304. [PMID: 32722601 DOI: 10.3390/ijms21155304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Shahcheraghi SH, Ayatollahi J, Aljabali AA, Shastri MD, Shukla SD, Chellappan DK, Jha NK, Anand K, Katari NK, Mehta M, Satija S, Dureja H, Mishra V, Almutary AG, Alnuqaydan AM, Charbe N, Prasher P, Gupta G, Dua K, Lotfi M, Bakshi HA, Tambuwala MM. An overview of vaccine development for COVID-19. Ther Deliv 2021;12:235-44. [PMID: 33624533 DOI: 10.4155/tde-2020-0129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
3 Cai H, Zhou R, Jiang F, Zeng Q, Yang H. Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy? Mult Scler Relat Disord 2022;58:103394. [PMID: 35216775 DOI: 10.1016/j.msard.2021.103394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Solmaz I, Anlar B. Immunization in multiple sclerosis and other childhood immune-mediated disorders of the central nervous system: A review of the literature. Eur J Paediatr Neurol 2021;33:125-34. [PMID: 34214824 DOI: 10.1016/j.ejpn.2021.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Jovicevic V, Ivanovic J, Momcilovic N, Andabaka M, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T, Drulovic J. Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment. Multiple Sclerosis and Related Disorders 2022;62:103794. [DOI: 10.1016/j.msard.2022.103794] [Reference Citation Analysis]
6 Apostolos-Pereira SL, Campos Ferreira L, Boaventura M, de Carvalho Sousa NA, Joca Martins G, d'Almeida JA, Pitombeira M, Silvestre Mendes L, Fukuda T, Souza Cabeça HL, Chaves Rocha L, Santos de Oliveira B, Vieira Stella CR, Lobato de Oliveira EM, de Souza Amorim L, Ferrari de Castro A, Pereira Gomes Neto A, Diogo Silva G, Bueno L, de Morais Machado M, Castello Dias-Carneiro R, Maciel Dias R, Porto Moreira A, Piccolo A, Kuntz Grzesiuk A, Muniz A, Diniz Disserol C, Ferreira Vasconcelos C, Kaimen-Maciel D, Sisterolli Diniz D, Comini-Frota E, Coronetti Rocha F, Cruz Dos Santos GA, Dadalti Fragoso Y, Sciascia do Olival G, Ruocco HH, Siqueira HH, Sato HK, Figueiredo JA Jr, Cortoni Calia L, Teixeira Dourado ME Jr, Scolari L, Ribeiro Soares Neto H, Melges L, Magno Gonçalves MV, Vellutini Pimentel ML, de Castro Ribeiro M, Gurrola Arambula O, Diniz da Gama P, Leite Menon R, Barbosa Thomaz R, de Rizo Morales R, Sobreira S, Machado SN, Gonsalves Jubé Ribeiro T, Coelho Santa Rita Pereira V, Maia Costa V, da Nóbrega Junior AW, Vieira Alves-Leon S, Mamprim de Morais Perin M, Donadi E, Adoni T, Gomes S, Brito Ferreira M, Callegaro D, Mendes MF, Brum D, von Glehn F; Neuroimmunology Brazilian Study Group. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm 2021;8:e1060. [PMID: 34446434 DOI: 10.1212/NXI.0000000000001060] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yin H, Zhang Y, Xu Y, Peng B, Cui L, Zhang S. The Impact of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorder Beyond Infection Risk. Front Neurol 2021;12:657037. [PMID: 33828524 DOI: 10.3389/fneur.2021.657037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xu Y, Cao Y, Ma Y, Zhao Y, Jiang H, Lu J, Zhao C, Quan C. COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style. Front Neurol 2021;12:717111. [PMID: 34421811 DOI: 10.3389/fneur.2021.717111] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Viswanathan S. Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources. Mult Scler Relat Disord 2020;44:102353. [PMID: 32653804 DOI: 10.1016/j.msard.2020.102353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Louapre C, Maillart E, Papeix C, Zeidan S, Biotti D, Lepine Z, Wahab A, Zedet M, Labauge P, Tilikete C, Pique J, Tourbah A, Mathey G, Dimitri Boulos D, Branger P, Kremer LD, Marignier R, Collongues N, De Seze J. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. Eur J Neurol 2021;28:3461-6. [PMID: 33103295 DOI: 10.1111/ene.14612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Jovicevic V, Ivanovic J, Andabaka M, Tamas O, Veselinovic N, Momcilovic N, Mesaros S, Pekmezovic T, Drulovic J. COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2022;57:103320. [PMID: 35158424 DOI: 10.1016/j.msard.2021.103320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]